These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 22029963)
1. MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. Scheerens H; Su Z; Irving B; Townsend MJ; Zheng Y; Stefanich E; Chindalore V; Bingham CO; Davis JC Arthritis Res Ther; 2011; 13(5):R177. PubMed ID: 22029963 [TBL] [Abstract][Full Text] [Related]
2. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis. Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046 [TBL] [Abstract][Full Text] [Related]
3. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Choy EH; Panayi GS; Emery P; Madden S; Breedveld FC; Kraan MC; Kalden JR; Rascu A; Brown JC; Rapson N; Johnston JM Rheumatology (Oxford); 2002 Oct; 41(10):1142-8. PubMed ID: 12364634 [TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. Emu B; Luca D; Offutt C; Grogan JL; Rojkovich B; Williams MB; Tang MT; Xiao J; Lee JH; Davis JC Arthritis Res Ther; 2012 Jan; 14(1):R6. PubMed ID: 22225620 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. van Vollenhoven RF; Keystone EC; Strand V; Pacheco-Tena C; Vencovský J; Behrens F; Racewicz A; Zipp D; Rharbaoui F; Wolter R; Knierim L; Schmeidl R; Zhou X; Aigner S; Dälken B; Wartenberg-Demand A; Ann Rheum Dis; 2018 Apr; 77(4):495-499. PubMed ID: 29343509 [TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study. Leng X; Tang X; Hu P; Guan X; Li Q; Huang C; Zhang Q; Chen R; Zeng X Front Immunol; 2022; 13():1110992. PubMed ID: 36926529 [TBL] [Abstract][Full Text] [Related]
8. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers. Lim JJ; Derby MA; Zhang Y; Deng R; Larouche R; Anderson M; Maia M; Carrier S; Pelletier I; Girard J; Kulkarni P; Newton E; Tavel JA Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559255 [TBL] [Abstract][Full Text] [Related]
9. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262 [TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753 [TBL] [Abstract][Full Text] [Related]
11. Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis. Hepburn TW; Totoritis MC; Davis CB Rheumatology (Oxford); 2003 Jan; 42(1):54-61. PubMed ID: 12509613 [TBL] [Abstract][Full Text] [Related]
12. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W; Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293 [TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. van der Lubbe PA; Dijkmans BA; Markusse HM; Nässander U; Breedveld FC Arthritis Rheum; 1995 Aug; 38(8):1097-106. PubMed ID: 7639806 [TBL] [Abstract][Full Text] [Related]
14. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Zheng Y; Scheerens H; Davis JC; Deng R; Fischer SK; Woods C; Fielder PJ; Stefanich EG Clin Pharmacol Ther; 2011 Feb; 89(2):283-90. PubMed ID: 21191378 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial. Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B; Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929 [TBL] [Abstract][Full Text] [Related]
16. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493 [TBL] [Abstract][Full Text] [Related]
17. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Choy EH; Chikanza IC; Kingsley GH; Corrigall V; Panayi GS Scand J Immunol; 1992 Aug; 36(2):291-8. PubMed ID: 1354392 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Choy EH; Connolly DJ; Rapson N; Jeal S; Brown JC; Kingsley GH; Panayi GS; Johnston JM Rheumatology (Oxford); 2000 Oct; 39(10):1139-46. PubMed ID: 11035136 [TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094 [TBL] [Abstract][Full Text] [Related]
20. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. Mason U; Aldrich J; Breedveld F; Davis CB; Elliott M; Jackson M; Jorgensen C; Keystone E; Levy R; Tesser J; Totoritis M; Truneh A; Weisman M; Wiesenhutter C; Yocum D; Zhu J J Rheumatol; 2002 Feb; 29(2):220-9. PubMed ID: 11838838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]